Focused On-demand Library for Programmed cell death protein 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q16342

UPID:

PDCD2_HUMAN

Alternative names:

Zinc finger MYND domain-containing protein 7; Zinc finger protein Rp-8

Alternative UPACC:

Q16342; E9PCU7; F5GYS7; Q58HM9; Q58HN0; Q9UH12

Background:

Programmed cell death protein 2, also known as Zinc finger MYND domain-containing protein 7 or Zinc finger protein Rp-8, is speculated to be a DNA-binding protein that plays a crucial role in cellular processes. Its potential regulatory function suggests it may be pivotal in cell death and proliferation, highlighting its importance in maintaining cellular homeostasis.

Therapeutic significance:

Understanding the role of Programmed cell death protein 2 could open doors to potential therapeutic strategies. Its involvement in key cellular functions such as cell death and proliferation makes it a promising target for drug discovery efforts aimed at treating diseases where these processes are dysregulated.